

**Supplementary Table S1.** Association between clinical variables with changes in carotid atheromatous plaque by period.

|                                                          | Atheromatous plaque regression |          |                      |              |
|----------------------------------------------------------|--------------------------------|----------|----------------------|--------------|
|                                                          | M6-M0                          |          | M12-M6               |              |
|                                                          | Odds ratio (95%CI)             | <i>p</i> | Odds ratio (95%CI)   | <i>p</i>     |
| Age                                                      | 0.976 (0.922-1.032)            | 0.396    | 1.014 (0.962-1.069)  | 0.598        |
| Men                                                      | NC                             | -        | 3.789 (0.364-39.412) | 0.265        |
| eGFR (mL/min/1.73 m <sup>2</sup> )                       | 0.995 (0.969-1.021)            | 0.684    | 1.019 (0.988-1.051)  | 0.233        |
| CKD-EPI (eGFR <60 mL/min/1.73 m <sup>2</sup> )           | 2.826 (0.687-11.621)           | 0.150    | 0.833 (0.238-2.914)  | 0.775        |
| Stage 4–5 CKD-EPI (eGFR <30 mL/min/1.73 m <sup>2</sup> ) | 0.833 (0.070-9.900)            | 0.885    | 0.000 (0.000-0.000)  | 1.000        |
| Years since onset                                        | 1.047 (0.956-1.148)            | 0.322    | 1.056 (0.985-1.133)  | 0.123        |
| Attack count                                             | 1.003 (0.988-1.018)            | 0.690    | 1.024 (0.993-1.056)  | 0.132        |
| Number of affected joints                                | 0.988 (0.822-1.187)            | 0.899    | 1.254 (0.984-1.596)  | 0.067        |
| Oligo or polyarticular presentation                      | 0.933 (0.230-3.781)            | 0.923    | 1.400 (0.321-6.109)  | 0.654        |
| Tophi                                                    | 0.389 (0.106-1.433)            | 0.156    | 1.500 (0.361-6.230)  | 0.577        |
| Colchicine                                               | NC                             | -        | 1.200 (0.070-20.429) | 0.900        |
| Colchicine (mg/day)                                      | 2.003 (0.127-31.504)           | 0.621    | 3.479 (0.424-28.523) | 0.246        |
| Prednisone                                               | 0.189 (0.016-2.255)            | 0.188    | 0.875 (0.051-14.872) | 0.926        |
| Prednisone (mg/day)                                      | 0.903 (0.506-1.610)            | 0.729    | 0.965 (0.693-1.345)  | 0.835        |
| ULT                                                      | NC                             | -        | NC                   | -            |
| Allopurinol                                              | 0.618 (0.093-4.106)            | 0.618    | 0.580 (0.114-2.944)  | 0.511        |
| Serum urate >6 mg/dL                                     | 0.970 (0.739-1.272)            | 0.824    | 1.225 (0.815-1.840)  | 0.329        |
| CRP (mg/dL)                                              | 0.889 (0.501-1.576)            | 0.686    | 0.435 (0.085-2.228)  | 0.318        |
| Total cholesterol (mg/dL)                                | 1.005 (0.990-1.020)            | 0.546    | 0.988 (0.963-1.014)  | 0.371        |
| Non-HDL cholesterol (mg/dL)                              | 1.003 (0.988-1.019)            | 0.676    | 0.990 (0.967-1.014)  | 0.421        |
| LDL cholesterol (mg/dL)                                  | 1.005 (0.988-1.021)            | 0.575    | 0.992 (0.958-1.027)  | 0.640        |
| HDL cholesterol (mg/dL)                                  | 1.007 (0.944-1.075)            | 0.823    | 0.963 (0.892-1.040)  | 0.337        |
| Triglycerides (mg/dL)                                    | 1.008 (0.996-1.020)            | 0.186    | 1.002 (0.993-1.011)  | 0.656        |
| Use of statins                                           | 0.985 (0.280-3.469)            | 0.981    | 0.667 (0.192-2.313)  | 0.523        |
| Use of high-potency statins                              | 1.429 (0.316-6.455)            | 0.643    | 0.172 (0.03–0.969)   | <b>0.046</b> |

NC: not calculable.

*p*-values were considered significant below 0.050 (bold).

M0: month 0 (baseline); M6: month 6; M12: month 12; CI: confidence interval; ULT: urate-lowering therapy; CRP: C-reactive protein; eGFR: estimated glomerular filtration rate; CKD-EPI: chronic kidney disease epidemiology collaboration; HDL: high-density lipoprotein; LDL: low-density lipoprotein.